Micromeritics Instrument Launches the SAS II for Particle Sizing
The device uses the air permeability technique to enhance the productivity and accuracy of particle sizing.
Micromeritics Instrument, a material characterization technology company based in Norcross, GA, announced the launch of the Sub-Sieve Autosizer II (SAS II), a device that enhances the productivity and accuracy of particle sizing via the air permeability technique, on Dec. 3, 2019.
According to a company press release, the autosizer comes equipped with fully automated measurement sequences which include computer-controlled sample compaction and pressure stability for high repeatability. Reports are generated automatically and can be customized to meet company requirements as security features lock down measurement methods and configuration parameters from unofficial changes.
The device handles particle size measurements from 0.2 µm to 75 µm by using the non-destructive air permeability technique to measure the pressure drop across a packed bed of sample at a defined air flow rate, accurately measuring finer powders, according to the release. Additionally, the autosizer functions with specific ASTM standards including E2980, E2651, B330-12, and B330-15 for metal powders and C721-15 for alumina and silica powders.
Source: Micromeritics Instrument
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
